NINnaemeka C. Iriemenam

Nnaemeka C. Iriemenam

*This is an algorithmically generated author record based on publicly available information.

Nnaemeka C. Iriemenam has a total of 384 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    High prevalence of SARS-CoV-2 antibodies among frontline healthcare workers during the COVID-19 pandemic in three states of Nigeria from August to December 2022

    by Nnaemeka C. Iriemenam, Sophia Osawe, Olusola A. Akanbi, Oluwaseun Akinmulero, Ado G. Abubakar, Mary Okoli, Rita Okonkwo, Oyewole Oyedele, Nifarta Andrew, Olumide Okunoye, et al.

    Background: Frontline healthcare workers (HCWs) are among the first professionals significantly impacted by epidemics and pandemics. During the COVID-19 pandemic, HCWs had an increased risk of infection. This study aimed to determine the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among Nigerian HCWs. Methods: A cross-sectional study of 1,247 randomly selected HCWs, was conducted across seven healthcare facilities in Nigeria, from August 2022 through December 2022 (Epi week 31−51). This study had two parts: the knowledge, attitude, and practices (KAP) survey and the seroprevalence of SARS-CoV-2 antibodies. Healthcare cadres enrolled were nurses, laboratorians, doctors, and pharmacists who provided informed consent before enrollment. An antigen-based COVID-19 rapid diagnostic test was used to screen all HCWs at enrollment, and a SARS-CoV-2 Multi-Antigen IgG assay was used to test for the presence of SARS-CoV-2 antibodies for the seroprevalence component of the study. Findings: A total of 1,247 HCWs were enrolled 682 (54.6%) nurses, 286 (22.9%) laboratorians, 222(18.0%) doctors, and 57(4.5%) pharmacists. The majority HCWs were males (70.5%), lived in urban areas (90.2%), had tertiary education (64.0%), and were married (81.7%). The proportion of HCWs that used drugs or smoked was 0.2%. The seropositivity of SARS-CoV-2 amongst HCWs was 98.2% of which 80.6% where due to the Nucleocapsid protein and 17.6% due to the Spike protein. Nurses were three times more likely to be seropositive for COVID-19 than laboratorians ( P < 0.05 ). Interpretation: Our findings reveal a high prevalence of SARS-CoV-2 antibodies among HCWs, especially among nurses. At the time of this study, half of the HCWs were unvaccinated for COVID-19. As frontline HCWs remain at increased risk of occupational exposure, this study highlights the need to strengthen infection prevention strategies, particularly vaccination and infection prevention and control measures, to protect the healthcare workforce.

  • Open Access

    Use of complementary indicators in trachoma surveys in Nigeria: results of impact surveys in two local government areas

    by Caleb Mpyet, Sunday Isiyaku, Joy Shu’AIbu, Teyil Wamyil-Mshelia, Grace Ajege, Suzie Madaki, Fatai Oyediran, Laura Senyonjo, Cristina Jimenez, E Michelle Taylor, et al.

    Objectives: Trachoma elimination progress is hampered in some districts by persistent or recrudescent trachomatous inflammation—follicular (TF). In Sokoto State, Nigeria, two local government areas (LGAs) have been classified as having persistent TF. We aimed to determine whether there was ongoing, programmatically significant conjunctival Chlamydia trachomatis (Ct) community transmission in these LGAs. Methods: In addition to examination for trachoma clinical signs, we took conjunctival swabs (for Ct nucleic acid amplification testing) from children aged 1–5 years, and dried blood spots [for estimation of anti-chlamydial plasmid gene protein 3 seroconversion rates (SCRs)] from children aged 1–9 years. Results: In Binji LGA, TF prevalence (4.1%) was below the elimination threshold, SCR was 1.1 per 100 child years in 1–5-year-olds, and Ct infection prevalence was 0.1%. In Silame LGA, TF prevalence (5.6%) was above the elimination threshold, but SCR was 1.6, and Ct infection prevalence was 0.2%. Conclusion: Binji has attained the active trachoma elimination threshold, thus transitioning to surveillance. In Silame, despite the TF prevalence remaining slightly above threshold, the low Ct infection prevalence and low SCR suggest Ct transmission is minimal, and mass drug administration will not be conducted. Silame can therefore also transition to the surveillance phase. Complementary trachoma survey indicators help ensure appropriate and cost-efficient programmatic decisions.

  • Risk Factors and Geospatial Associations With Plasmodium falciparum Malaria Infection and IgG Seroprevalence: Nigeria, 2018

    by Alicia Jaramillo-Underwood, Abiodun Ogunniyi, Hong Zhou, Perpetua Uhomoibhi, Nwando Mba, Nnaemeka Ndodo, Ayuba B Dawurung, Ado G Abubakar, McPaul I Okoye, Nnaemeka C Iriemenam, et al.

    Background: Nigeria consistently shows the greatest population burden of Plasmodium falciparum (Pf) malaria. While rapid diagnostic tests and microscopy offer valuable information for clinical decisions and prevalence estimates, serological tools provide more nuanced information on exposure history, enhancing the ability to assess and track malaria burden at a population level. Methods: Blood samples (n = 89 438) from a nationwide 2018 human immunodeficiency virus household survey in Nigeria were assayed for active/recent infection by testing for the Pf HRP2 and LDH antigens, and for Pf exposure by immunoglobulin G carriage against a panel of antigens. Risk factors for Pf infection and exposure were assessed using logistic regression and geospatial analyses. Results: By blood antigenemia, current/recent Pf prevalence was 38.3% (95% CI: 37.2%–39.5%), and seroprevalence among the panel of 5 Pf antigens ranged from 48% to 87%. In multivariate regression models, participants age 5–14 years had the highest odds of active infection versus children <5 years. Compared with the lowest wealth category, the wealthiest category showed a 5-fold reduction in odds of active infection, and urban living was associated with a 30% reduction. In estimating a longer window of Pf exposure, serology recapitulated these associations with the highest wealth category showing a 10-fold reduction, and urban living a 60% reduction, in exposure. Conclusions: Geospatial findings underscored Nigeria's hyperendemic but heterogeneous malaria epidemiology with infection and exposure are not unequally distributed among the populace. Serological data can provide greater insights into malaria risk factor analyses and augment examination of spatial heterogeneities in transmission.

  • Open Access

    Field validation and application of the luminex triplex HIV assay to estimate HIV prevalence and HIV-1 incidence in Nigeria

    by Ernest L. Yufenyuy, Olusola A. Akanbi, Vedapuri Shanmugam, Kelsie Decker-Pulice, Jeni Vuong, Mervi Detorio, Amy Zheng, Orji Bassey, Ado G. Abubakar, Oluwaseun Akinmulero, et al.

    HIV cross-sectional surveys require multi-layered testing with several tests to estimate HIV prevalence and HIV-1 incidence. We evaluated the performance and accuracy of the newly developed HIV Triplex assay to diagnose HIV-1 and HIV-2 and detect HIV-1 recent infections using plasma samples from the 2018 Nigeria AIDS Indicator and Impact Survey (NAIIS). Plasma samples from consenting HIV-positive (n=2,773) and a subset of HIV-negative samples (n=7,196), as determined by the national rapid testing algorithm, followed by Bio-Rad Geenius HIV-1/2 Supplemental Assay and Western Blot, aged 18 months - 64 years, were tested using the Luminex-based HIV Triplex assay. The assay classified specimens as HIV-1 positive, HIV-2 positive, dual (HIV-1 & 2) infections, or HIV-seronegative. All HIV-1 and dual infections were further classified as either HIV-1 recent (kappa of 0.987 when compared to NAIIS survey results. Percent agreement between the HIV Triplex assay and the LAg-Avidity EIA for recent and LT classification was 98.86% with a kappa of 0.80 [CI: 0.71-0.89] and a Spearman-ranked correlation (ρ) of 0.689. A small number (n=45; 0.63%) of the subset of negatives tested were classified by the multiplex assay as either HIV-1 positive (n=35) or HIV-2 positive (n=10). Nevertheless, the HIV Triplex assay agreed with NAIIS HIV-negative survey results (99.37%). Using these results as they were, unweighted estimates of HIV prevalence for both HIV Triplex assay and NAIIS test results were similar (1.62% [95% CI: 1.56-1.68] and 1.60% [95% CI: 1.54-1.66], respectively) with overlapping confidence. After adjusting for viral load and anti-retroviral therapy, HIV-1 unweighted incidence for ages ≥15 years, using HIV Triplex assay data, was 0.70 per 1,000 [95% CI: 0.40-0.90]. This is similar to the unweighted incidence using the LAg-based RITA (recent infection testing algorithm) of 0.80 per 1,000 [95% CI: 0.60-1.10]. The HIV Triplex assay combines several assays in one, providing highly accurate results for estimating HIV prevalence and HIV-1 incidence in surveys. This assay has the potential to simplify cross-sectional surveys making them less expensive, easier, and quicker.

  • Open Access

    Lessons learnt from laboratory capacity building in supporting integrated disease serosurveillance using a multiplex bead assay in Nigeria

    by Ado G. Abubakar, Mary Okoli, Oluwaseun O. Akinmulero, Andrew Thomas, Temitope A. Olaleye, Simon Gabo, Samuel S. Awala, Felicia Nwatu, Blessing Ugboaja, Ifeanyi Odoh, et al.

    Background: Serologic assays can monitor population exposure to pathogens and immunity to vaccine-preventable diseases; the multiplex bead assay (MBA) can test for multiple analytes simultaneously. Intervention: Specimens collected during the Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS) were used to estimate the seroprevalence of diseases of public health importance, and specimens collected from special studies were used to estimate the seroprevalence of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) to improve the surveillance programmes. In 2019, Luminex MAGPIX® instruments were installed at the MBA laboratory in the National Reference Laboratory, Nigeria Centre for Disease Control and Prevention, in Abuja, Nigeria. Dried blood spot specimens from the NAIIS, stored with consent for future testing, were prioritised for testing. Between 2019 and 2022, the National Reference Laboratory MBA laboratory conducted antibody and antigen assays for an estimated 130 000 NAIIS participants, completed two rounds of coronavirus disease 2019 (COVID-19) serosurveys, and validated SARS-CoV-2 serological assays for use in Nigeria. Lessons learnt: The data generated by the MBA laboratory supported funding requests for childhood immunisation and the application of the National Malaria Elimination Programme Global Fund. The MBA results strengthened the National HIV Serial Rapid Testing Algorithm. During the COVID-19 pandemic, the laboratory validated a SARS-CoV-2 MBA, which measured antibodies against three antigens. This multi-target assay was used to complete two additional rounds of the COVID-19 household serosurvey in Nigeria. Recommendations: This strategy of investing in MBA laboratory capacity building could serve as a model for other nations seeking to fortify their public health infrastructure. What this study adds: Nigeria’s integrated disease surveillance capability was boosted through MBA technology.


  • Open Access

    SARS-CoV-2 serologic surveillance among people living with HIV in Nigeria, April 2022 to January 2023

    by Helen M. Chun, Sophia Osawe, Samuel Adams-Dabban, Jennifer Favaloro, Nnaemeka C. Iriemenam, Emilio Dirlikov, Diana Martin, Kyle Milligan, Andrew Abutu, Olumide Okunoye, et al.


  • Open Access

    Seroprevalence and Risk Factors for Toxoplasma gondii Infection in Women of Reproductive Age in Nigeria in 2018

    by Dawn Blackburn, Nwando Mba, William Nwachukwu, Hong Zhou, Andrew Hill, Andrew Abbott, Nishanth Parameswaran, Samuel Awala, Stacie Greby, Matthias Alagi, et al.

    : Congenital transmission of Toxoplasma gondii can occur when a woman becomes infected for the first time during or just before pregnancy. Toxoplasma gondii in the fetus can lead to miscarriage, stillbirth, ocular or neurological abnormalities at birth, or progressive visual, hearing, motor, and cognitive deficiencies. The national seroprevalence of T. gondii infection in Nigeria was previously unknown. The 2018 Nigeria HIV/AIDS Indicator and Impact Survey collected demographic, socioeconomic, and HIV-related data and stored blood specimens with consent for future analysis for other pathogens of public health importance. We evaluated toxoplasmosis seropositivity and risk factors in a sample of 44,269 women of reproductive age (WRA) between 15 and 44 years. The national T. gondii seroprevalence among WRA was 26.8% (95% CI: 25.8–27.7%). We found that WRA from all 36 states and the Federal Capital Territory had T. gondii exposure. Seroprevalence was higher in 25- to 44-year-olds than in 15- to 24-year-olds. A similar proportion of pregnant and nonpregnant women were seropositive. Increased odds of seropositivity were associated with unimproved toilet facilities and drinking water sources, being in a higher wealth quintile, and primary and secondary education compared with no education. Decreased odds of seropositivity were associated with living in an urban area and owning livestock. This study provides the first-ever national seroprevalence estimate for WRA in Nigeria. Although information on known risk factors for toxoplasmosis (e.g., consumption of undercooked meat, cat ownership) was not collected, future studies could further investigate potential risk factors to inform the development of effective toxoplasmosis prevention measures.


  • Open Access

    Schistosomiasis Seroprevalence among Children Aged 0–14 Years in Nigeria, 2018

    by Anne Straily, Israel Tamunonengiyeofori, Ryan E. Wiegand, Nnaemeka C. Iriemenam, McPaul I. Okoye, Ayuba B. Dawurung, Nkechi Blessing Ugboaja, Martha Tongha, Nishanth Parameswaran, Stacie M. Greby, et al.

    The first nationally representative, population-based study of schistosomiasis seroprevalence in Nigeria was conducted using blood samples and risk-factor data collected during the 2018 Nigeria HIV/AIDS Indicator and Impact Survey (NAIIS). Schistosomiasis seroprevalence was estimated by analyzing samples for reactivity to schistosome soluble egg antigen (SEA) in a multiplex bead assay; NAIIS survey data were assessed to identify potential risk factors for seropositivity. The SEA antibody data were available for 31,459 children aged 0 to 14 years. Overall seroprevalence was 17.2% (95% CI: 16.3–18.1%). Seropositive children were identified in every age group, including children < 5 years, and seroprevalence increased with increasing age (P < 0.0001). Several factors were associated with increased odds of seropositivity, including being a boy (odds ratio [OR] = 1.34, 95% CI: 1.24–1.45), living in a rural area (OR = 2.2, 95% CI: 1.9–2.5), and animal ownership (OR = 1.67, 95% CI: 1.52–1.85). Access to improved sanitation and drinking water sources were associated with decreased odds of seropositivity (OR = 0.52, 95% CI: 0.47–0.58 and OR = 0.53, 95% CI: 0.47–0.60, respectively) regardless of whether the child lived in a rural (sanitation: adjusted odds ratio [aOR] = 0.7, 95% CI: 0.6–0.8; drinking water: aOR = 0.7, 95% CI: 0.6–0.8) or urban area (sanitation: aOR = 0.6, 95% CI: 0.5–0.7; drinking water: aOR = 0.5, 95% CI: 0.4–0.6), highlighting the importance of these factors for schistosomiasis prevention and control. These results identified additional risk populations (children < 5 years) and a new risk factor (animal ownership) and could be used to monitor the impact of control programs.


  • Open Access

    Lessons learnt from assessing and improving accuracy and positive predictive value of the national HIV testing algorithm in Nigeria

    by Augustine O. Mpamugo, Nnaemeka C. Iriemenam, Adebobola Bashorun, Olumide O. Okunoye, Orji O. Bassey, Edewede Onokevbagbe, Tapdiyel Jelpe, Matthias A. Alagi, Chidozie Meribe, Rose E. Aguolu, et al.

    Background: HIV testing remains an entry point into HIV care and treatment services. In 2007, Nigeria adopted and implemented a two-test rapid HIV testing algorithm of three HIV rapid test kits, following the sequence: Alere Determine (first test), UnigoldTM (second test), and STAT-PAK® as the tie-breaker. Sub-analysis of the 2018 Nigeria HIV/AIDS Indicator and Impact Survey data showed significant discordance between the first and second tests, necessitating an evaluation of the algorithm. This manuscript highlights lessons learnt from that evaluation. Intervention: A two-phased evaluation method was employed, including abstraction and analysis of retrospective HIV testing data from January 2017 to December 2019 from 24 selected sites supported by the United States President’s Emergency Plan for AIDS Relief programme. A prospective evaluation of HIV testing was done among 2895 consecutively enrolled and consented adults, aged 15–64 years, accessing HIV testing services from three selected sites per state across the six geopolitical zones of Nigeria between July 2020 and September 2020. The prospective evaluation was performed both in the field and at the National Reference Laboratory under controlled laboratory conditions. Stakeholder engagements, strategic selection and training of study personnel, and integrated supportive supervision were employed to assure the quality of evaluation procedures and outcomes. Lessons learnt: The algorithm showed higher sensitivity and specificity in the National Reference Laboratory compared with the field. The approaches to quality assurance were integral to the high-quality study outcomes. Recommendations: We recommend comparison of testing algorithms under evaluation against a gold standard. What this study adds: This study provides context-specific considerations in using World Health Organization recommendations to evaluate the Nigerian national HIV rapid testing algorithm.

  • Open Access

    Treponemal Antibody Seroprevalence Using a Multiplex Bead Assay from Samples Collected during the 2018 Nigeria HIV/AIDS Indicator and Impact Survey: Searching for Yaws in Nigeria

    by Sarah Anne J. Guagliardo, Nishanth Parameswaran, Ndidi Agala, Ado Abubakar, Gretchen Cooley, Tun Ye, Mary Kamb, Nwando Mba, Nwachukwu William, Stacie Greby, et al.

    Yaws is a chronic, relapsing disease of skin, bone, and cartilage caused by Treponema pallidum subsp. pertenue. Yaws was last reported in Nigeria in 1996, although neighboring countries have recently reported cases. We investigated serological evidence for yaws among children aged 0–14 years in Nigeria by measuring antibodies to the treponemal antigens rp17 and TmpA in blood specimens from a 2018 nationally representative HIV survey using a multiplex bead assay. The presence of antibodies to both antigens (“double positive”) likely reflects current or recent treponemal infection. Overall, 1.9% (610/31,549) of children had anti-TmpA antibodies, 1.5% (476/31,549) had anti-rp17 antibodies, and 0.1% (39/31,549) were double positive. Among households, 0.5% (84/18,021) had a double-positive child, with a clustering of double-positive children. Although numbers are low, identification of antibodies to both TmpA and rp17 may warrant investigation, including more granular epidemiologic and clinical data, to assess the potential for continuing yaws transmission in Nigerian children.